WYETH VERDIA LABELING SHOULD MENTION LIVER ENZYME ABNORMALITIES OF UNKNOWN CLINICAL SIGNIFICANCE, FDA CMTE. SAYS IN RECOMMENDING APPROVAL OF AII INHIBITOR
Executive Summary
Liver function test abnormalities found in clinical studies of Wyeth-Ayerst's angiotensin II inhibitor Verdia (tasosartan) should be referenced in labeling but should not be presumed to reflect a difference between tasosartan and other members of the class, FDA's Cardiovascular & Renal Drugs Advisory Committee recommended Jan. 27.